Diabetic Foot Care — Cost, Top Hospitals & Success Rates | MyMedicPlus

Diabetic foot care within diabetology addresses the prevention and early management of foot complications arising from diabetes-related peripheral neuropathy, peripheral arterial disease, and impaired wound healing. Approximately 15% of people with diabetes develop a foot ulcer during their lifetime, and without appropriate care, 15–20% of these ulcers lead to lower limb amputation. The diabetologist plays a central coordinating role in the multidisciplinary foot care team — ensuring optimal glycaemic control, cardiovascular risk management, and timely referral to podiatry, vascular surgery, and orthopaedic surgery as required.

The diabetologist's approach to foot care begins with systematic annual risk stratification. The IWGDF risk classification categorises patients by the presence of peripheral neuropathy (assessed with 10g monofilament, 128 Hz tuning fork, and ankle reflexes), peripheral arterial disease (palpable pulses, ABPI if pulses absent or symptoms present), prior amputation, foot deformity, and history of previous ulceration. High-risk patients receive intensified monitoring with 1–3 monthly podiatric review, therapeutic footwear prescription, and structured foot care education.

When foot complications develop, the diabetologist coordinates with the multidisciplinary team: the podiatrist for debridement and offloading, the vascular surgeon for revascularisation assessment, the infectious disease specialist for antibiotic selection in infected ulcers, and the orthopaedic surgeon for Charcot neuroarthropathy management or bone resection in osteomyelitis.

The diabetology foot care pathway addresses the full spectrum of diabetic foot complications. Peripheral diabetic neuropathy — present in 50% of patients with diabetes duration over 20 years — is the primary risk factor for foot ulceration, causing loss of protective sensation and autonomic dysfunction (dry skin, fissuring, predisposing to infection). Risk stratification using monofilament and vibration testing identifies patients for intensified surveillance before ulceration occurs.

Diabetic foot ulcers, classified from Grade 1 (superficial, no infection) to Grade 5 (gangrene involving the whole foot) using the Wagner scale, or the more nuanced IWGDF/IDSA classification that incorporates wound depth, ischaemia, and infection severity, guide treatment intensity. Charcot neuroarthropathy — an acute inflammatory process causing bone and joint destruction in the neuropathic foot — requires immediate recognition, immobilisation in a total contact cast, and prolonged offloading over 6–18 months. Infected diabetic foot wounds require prompt microbiological assessment and targeted antibiotic therapy.

All people with diabetes should undergo annual foot examination. Those with neuropathy confirmed on monofilament testing, reduced or absent foot pulses, foot deformity (claw toes, Charcot deformity, prominent metatarsal heads), previous ulceration, or previous amputation should be reviewed by a podiatrist every 1–3 months. Patients with active foot ulcers require urgent same-week or next-day assessment by the multidisciplinary foot care team.

Patients not appropriate for aggressive wound management include those with end-stage terminal illness where comfort is the primary goal, those with extensive irreversible tissue necrosis, and those who prefer primary amputation following fully informed discussion. The decision between aggressive wound management and amputation requires sensitive multidisciplinary discussion involving the patient, family, diabetologist, vascular surgeon, and rehabilitation team. Patient selection for each treatment modality requires comprehensive pre-treatment evaluation including clinical history, physical examination, and relevant investigations. Patients who are poor candidates for one approach may still benefit from alternative treatment options within the same condition's management pathway.

Prevention is the primary treatment modality in diabetology foot care. Therapeutic footwear — custom-moulded insoles within depth shoes that distribute plantar pressure away from vulnerable areas — reduces foot ulcer recurrence by 40–60%. Podiatric nail and callus care at 1–3 monthly intervals prevents the minor skin trauma that triggers ulceration in neuropathic feet. Patient education on daily self-examination, prompt reporting of any skin breakdown, and footwear selection forms the cornerstone of preventive care.

For established neuropathic foot ulcers, treatment involves total contact casting or irremovable cast walker (gold-standard offloading), debridement of necrotic tissue and callus, wound dressing selection based on wound characteristics, and optimisation of systemic risk factors (HbA1c, blood pressure, lipids, smoking cessation). For infected ulcers, antibiotic therapy targeting likely pathogens (Staphylococcus aureus, streptococcal species) is initiated empirically and adjusted on culture results. Osteomyelitis requires 6–12 weeks of targeted antibiotics, often with surgical debridement or bone resection. Multidisciplinary diabetic foot clinics — combining podiatry, vascular surgery, orthotics, infectious disease, and endocrinology — deliver superior outcomes to single-specialty management for complex diabetic foot pathology. Shared decision-making between the patient and specialist ensures the chosen modality aligns with individual anatomy, comorbidities, risk tolerance, and personal goals. A formal consultation with a board-certified specialist, review of pre-treatment imaging or investigation results, and multidisciplinary team input for complex cases are standard practice before finalising the treatment plan.

Structured multidisciplinary diabetic foot programmes reduce major amputation rates by 50–80% compared to standard care without dedicated foot teams. Preventive podiatric care reduces foot ulcer incidence by 40–60% in high-risk patients. For established ulcers, healing rates of 65–80% are achievable in specialised centres within 12–20 weeks for neuropathic wounds with adequate perfusion. Prevention of major amputation is the critical outcome — major amputation in people with diabetes carries 5-year mortality rates of 40–70%, comparable to many cancers. Every prevented amputation represents a life-altering outcome for the patient. Regular podiatry surveillance and foot care education in diabetes clinics reduce major amputation rates by 50–85% in high-risk patients with prior ulceration, highlighting the transformative impact of preventive foot care on diabetic limb salvage outcomes.

Without adequate diabetic foot care, foot ulcers are the precursor to 80% of diabetes-related amputations. Infected ulcers with deep space involvement carry a 15–30% risk of major amputation within 6 months. Osteomyelitis underlying an ulcer markedly increases amputation risk. Charcot neuroarthropathy if unrecognised and left without offloading leads to catastrophic bone collapse and chronic deformity requiring lifelong orthotic management.

Iatrogenic complications include pressure injuries from improper casting, antibiotic adverse effects (C. difficile colitis, nephrotoxicity with certain agents), and surgical complications from debridement or bone resection procedures. The risk of recurrent ulceration after healing is high: approximately 40% within 1 year and 65% within 5 years, emphasising the need for lifelong preventive footwear and podiatric surveillance. Patients with active Charcot neuroarthropathy are at particular risk of misdiagnosis (confusion with osteomyelitis or cellulitis) — MRI is the most sensitive investigation and specialist referral to a dedicated Charcot clinic prevents the catastrophic collapse and instability that results from inappropriate weight-bearing during the active phase.

Post-ulcer healing follow-up is intensive given the high recurrence risk. Monthly podiatric review for the first 3 months post-healing assesses skin integrity, callus formation, footwear fit, and the presence of early pressure changes. Custom therapeutic footwear is prescribed and fitted within 2–3 months of healing. Annual diabetes foot check continues lifelong with reassessment of neuropathy, pulses, and footwear adequacy.

Patients discharged from active wound care should receive a written foot care plan, emergency contact details for the foot care team, and clear instructions on when to seek immediate medical attention (new ulcer, increasing redness, warmth, swelling, purulent discharge, fever, or systemic deterioration). Concurrent diabetes management optimisation — HbA1c, blood pressure, lipids — reduces recurrence risk.

Diabetic foot care represents one of the most expensive complications of diabetes. In the US, treating a complex infected foot ulcer with hospitalisation costs $30,000–$100,000; major amputation carries lifetime costs of $500,000+. Preventive care — annual foot examination, therapeutic footwear ($200–$600/year), and podiatric review ($80–$200 per session) — is highly cost-effective.

At specialised diabetic foot care centres in India, podiatric review costs $20–$60 per visit, wound care sessions $30–$100, and total contact casting $100–$300 per application. Hospitalisation for infected foot ulcers at JCI-accredited Indian centres costs $1,500–$6,000 — 70–90% less than US rates. These centres see high patient volumes and maintain expertise in limb-salvage surgery comparable to leading Western centres. Total cost of a major lower extremity amputation — including hospitalisation, rehabilitation, prosthetics, and long-term disability — exceeds USD 500,000 per patient lifetime, making preventive diabetic foot care highly cost-effective even at significant investment per screening visit.

For wounds not responding to standard debridement and offloading, advanced wound therapies include negative pressure wound therapy (NPWT/VAC therapy), bioengineered skin substitutes (Apligraf, Dermagraft), autologous platelet-rich plasma, and hyperbaric oxygen therapy (HBOT). HBOT — breathing 100% oxygen at increased atmospheric pressure — increases tissue oxygen tension and promotes healing in ischaemic wounds; it is recommended (IWGDF grade B) for selected Wagner Grade 3–4 wounds with ischaemia.

Primary amputation at the most distal viable level remains the appropriate treatment when limb salvage is not achievable or when the patient's rehabilitation potential and quality of life would be better served by prompt amputation and prosthetic limb fitting rather than prolonged failed wound management. Modern below-knee and Syme's amputation outcomes with prosthetic rehabilitation are far better than historically, and should not be delayed unnecessarily when limb salvage is futile.